New York, January 04, 2019: The scope of the report includes a detailed study of global and regional markets for various types of nuclear medicine market with the reasons given for variations in the growth of the industry in certain regions.
Nuclear medicine is special category in medical branch used for diagnosis and treatment of disease in a safe and painless way. Nuclear medicine contain radioactive material which combined called as radiopharmaceutical. The small quantity of radiopharmaceutical is given into human body in the form of injection or swallowing. It goes to specific location of a body where there could be disease or abnormality. It emits radiation called gamma rays and contains gamma camera which helps nuclear medicine physician to see inside the body. It takes pictures of inner body which helps physician to diagnose patients’ disease.
Browser Full Report @: https://www.marketresearchengine.com/reportdetails/nuclear-medicine-market
Reasons to buy this Report:
1) Obtain the most up to date information available on all active and planned nuclear medicine industry globally.
2) Identify growth segments and opportunities in the industry.
3) Facilitate decision making on the basis of strong historic and forecast of nuclear medicine industry and unit capacity data.
4) Assess your competitor’s refining portfolio and its evolution.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Cardinal Health, Inc. (U.S.), GE Healthcare (U.K.), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), Bayer Healthcare (Germany), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), and Mallinckrodt plc (Ireland).. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.
The nuclear medicine market is expected to exceed more than US$ 5.5 billion by 2023 growing at around 9.0% CAGR for the given forecast period.
The Nuclear Medicine Market has been segmented as below:
The Global Nuclear Medicine Market is segmented on the lines of Procedural Volume Segment Analysis, Type Analysis, Application Analysis and Regional Analysis. By Procedural Volume Segment Analysis this market is segmented on the basis of Diagnostics, SPECT Radiopharmaceuticals, PET Radiopharmaceuticals, Therapeutics, Beta Emitters, Alpha Emitters and Brachytherapy Isotopes. By Type Analysis this market is segmented on the basis of Diagnostics, SPECT Radiopharmaceuticals, Tc-99, Tl-201, Ga-67, I-123, PET Radiopharmaceuticals, F-18, Ru-82, Others, Therapeutics, Beta Emitters, I-131, Sm-153, Rh-186, Y-90, Lu-177, Others, Alpha, Emitters, Ra-223, Brachytherapy Isotopes, I-125, Ir-192, Pa-103, Cs-131 and Others.
By Application Analysis this market is segmented on the basis of Diagnostics, SPECT, Cardiology, Lymphoma, Thyroid, Neurology, Others, PET, Oncology, Cardiology, Neurology, Others, Therapeutics, Thyroid, Bone Metastasis, Lymphoma, Endocrine Tumors, Others. By Regional Analysis this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World.
Market Research Engine has published a new report titled as “Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT – Technetium, PET – F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90) & by Application (Oncology, Thyroid, Cardiology) – Global Forecasts to 2021”.
Request Sample Report from here: https://www.marketresearchengine.com/reportdetails/nuclear-medicine-market
Table of Contents
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
5.2 Market Dynamics
126.96.36.199 Investments Through Public-Private Partnerships to Modernize Diagnostic Imaging Centers
188.8.131.52 Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
184.108.40.206 Advances in Radiotracers
220.127.116.11 Increasing Incidence and Prevalence of Cancer and Cardiac Ailments
18.104.22.168 Shorter Half-Life of Radiopharmaceuticals
22.214.171.124 High Cost of Nuclear Medicine Equipment
126.96.36.199 High Demand in Emerging Markets
188.8.131.52 Upcoming Radioisotopes
184.108.40.206 Use of Radiopharmaceuticals in Neurological Applications
220.127.116.11 Shutdown of Nuclear Reactors
6 Nuclear Medicine Market, By Type
7 Nuclear Medicine Market, By Application
8 Nuclear Medicine Market, By Procedural Volume
9 Global Nuclear Medicine Market, By Region
10 Global Nuclear Medicine Market, By Region
11 Competitive Landscape
12 Company Profiles
12.2 Cardinal Health, Inc.
12.3 Mallinckrodt PLC
12.4 GE Healthcare (A Fully Owned Subsidiary of General Electric Company)
12.5 Lantheus Medical Imaging, Inc.
12.6 Bayer AG
12.7 Bracco Imaging S.P.A
12.8 Eczacibasi-Monrol Nuclear Products
12.9 Nordion, Inc. (A Subsidiary of Sterigenics International LLC.)
12.10 Advanced Accelerator Applications S.A.
12.11 IBA Molecular
Other Related Market Research Reports:
Company Name: Market Research Engine
Contact Person: John Bay
Country: United States
The post Nuclear Medicine/Radiopharmaceuticals Market to Surpass US$ 5.5 Billion By 2023 appeared first on Herald Keeper.